Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026

Madrigal Pharmaceuticals (Nasdaq: MDGL) will release first-quarter 2026 financial results on Wednesday, May 6, 2026, prior to the U.S. market open.

Rhea-AI Summary

Madrigal Pharmaceuticals (Nasdaq: MDGL) will release first-quarter 2026 financial results on Wednesday, May 6, 2026, prior to the U.S. market open. Management will host a live webcast at 8:00 a.m. Eastern Time to review financial and operating results, accessible via the company Investor Relations website.

The live webcast is recommended to be accessed by registering at least 15 minutes early and will be available on-demand about two hours after the live event.

Argus Apr 22 session

+0.27% close to close Open Argus

Details

News Market Reaction – MDGL

In the Apr 22 session, MDGL gained 0.27%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets the date and time for Madrigal’s first‑quarter 2026 results and webcast, cont...

Analysis

This announcement sets the date and time for Madrigal’s first‑quarter 2026 results and webcast, continuing its practice of early earnings scheduling. Investors can monitor this event alongside the company’s prior full‑year 2025 results and recent operational updates to gauge continuity in sales, cash position, and strategic progress. Attention will likely center on how Q1 performance compares to the strong 2025 baseline already disclosed.

Key Figures

Earnings release date: May 6, 2026 Webcast time: 8:00 a.m. Eastern Time Registration lead time: 15 minutes +1 more

Earnings release date

May 6, 2026

First-quarter 2026 financial results release before U.S. market open

Webcast time

8:00 a.m. Eastern Time

Management webcast to review Q1 2026 results

Registration lead time

15 minutes

Recommended minimum time before webcast start to register

Webcast replay delay

2 hours

Time after live webcast when replay becomes available

Previous Earnings date Reports

1 past event · Latest: Feb 02

Same Type 1 event

1. Feb 02

   Earnings date announcement

   24h Move

   +0.1%

   Set Q4 and full-year 2025 results date and webcast details.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CONSHOHOCKEN, Pa., April 22, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its first-quarter 2026 financial results on Wednesday, May 6, 2026, prior to the open of the U.S. financial markets.

Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results.

The live webcast may be accessed at the Investor Relations section of the Madrigal Pharmaceuticals website. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.

The webcast will be available approximately two hours after the live webcast.

About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com.

Investor Contact
Tina Ventura, Madrigal Pharmaceuticals, Inc., IR@madrigalpharma.com

Media Contact
Christopher Frates, Madrigal Pharmaceuticals, Inc., media@madrigalpharma.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Madrigal Pharmaceuticals (MDGL) release Q1 2026 results and hold the webcast?

Madrigal will release Q1 2026 results on May 6, 2026, before market open, with a live webcast at 8:00 a.m. ET. According to the company, management will review financial and operating results during the webcast and the replay will be available about two hours later.

How can investors access the MDGL May 6, 2026 webcast for first-quarter 2026 results?

Investors can access the webcast via the Investor Relations section of Madrigal's website and should register in advance. According to the company, participants are recommended to register at least 15 minutes before the 8:00 a.m. ET start to ensure a timely connection.

Will Madrigal (MDGL) provide an on-demand replay of the May 6, 2026 webcast and when?

Yes. The webcast replay will be available approximately two hours after the live event on the company's Investor Relations site. According to the company, the on-demand version allows investors who miss the live 8:00 a.m. ET presentation to review the results later the same day.

What should shareholders do to prepare for Madrigal's (MDGL) Q1 2026 webcast on May 6, 2026?

Shareholders should register on the Investor Relations webcast page and join at least 15 minutes before 8:00 a.m. ET to secure connection. According to the company, early registration helps avoid delays and ensures access to the live review of financial and operating results.